B
Belinda M Dcosta
Researcher at New York University
Publications - 21
Citations - 729
Belinda M Dcosta is an academic researcher from New York University. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 9, co-authored 12 publications receiving 261 citations.
Papers
More filters
Posted ContentDOI
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
Takuya Tada,Belinda M Dcosta,Marie I. Samanovic-Golden,Ramin S. Herati,Amber Cornelius,Mark J. Mulligan,Nathaniel R. Landau +6 more
TL;DR: Findings suggest that antibodies elicited by primary infection and by the BNT162b2 mRNA vaccine are likely to maintain protective efficacy against SARS-CoV-2 variants but that the partial resistance of virus with the B.1.1-1.351 spike protein could render some individuals less well protected, supporting a rationale for the development of modified vaccines containing E484K.
Posted ContentDOI
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Takuya Tada,Hao Zhou,Marie I. Samanovic,Belinda M Dcosta,Amber Cornelius,Mark J. Mulligan,Nathaniel R. Landau +6 more
TL;DR: In this paper, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared, showing that BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants.
Journal ArticleDOI
An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
Takuya Tada,Chen Fan,Jennifer S. Chen,Ramanjit Kaur,Kenneth A. Stapleford,Harry B. Gristick,Belinda M Dcosta,Craig B. Wilen,Crina M. Nimigean,Nathaniel R. Landau +9 more
TL;DR: An improved soluble ACE2 is reported, termed a “microbody” in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain and it inhibits entry of β coronaviruses and virus with the variant D614G spike.
Posted ContentDOI
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
TL;DR: In this paper, the authors tested monoclonal antibodies REGN10933 and REGN10987 that are used in combination, for their ability to neutralize SARS-CoV-2 variants B.1.7, mink cluster 5 and COH.
Journal ArticleDOI
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Takuya Tada,Belinda M Dcosta,Marie I. Samanovic,Ramin S. Herati,Amber Cornelius,Hao Zhou,Ada Vaill,Wes Kazmierski,Mark J. Mulligan,Nathaniel R. Landau +9 more
TL;DR: In this article, the authors show that convalescent-phase sera neutralize pseudotyped viruses with the B.1.7, B.351 and B. 1.248 with only a 3fold decrease in titer, an effect attributable to E484K.